Executive Management Team

Dr Miroslav Reljanović

Executive Chairman

Dr Miroslav Reljanović

Executive Chairman

Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, Croatia, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro co-founded PrimeVigilance in 2008, that quickly became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry, winning the Queen’s Award for enterprise in 2014 and again in 2019.

In July 2014 Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange and the subsequent completion of numerous acquisitions and secondary offerings.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its operations.

Miro is Chair of Ergomed’s Nomination Committee.

Richard Barfield

Chief Financial Officer

Richard Barfield

Chief Financial Officer

Richard joined Ergomed as Chief Financial Officer in June 2019. Since qualifying as a chartered accountant, Richard has more than 25 years’ experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of an NHS Foundation Trust.
Richard has proven experience within the contract research sector, having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m and deliver significant returns to its investors.

Roy Ovel

Chief Commercial Officer

Roy Ovel

Chief Commercial Officer

Roy Ovel has a wealth of experience working for more than 30 years in international business development with some of the leading global CROs. He has experience of working globally with virtual as well as large pharma across the drug development continuum. His reputation as a leader with strong commercial acumen focused on working with customers to really meet their needs is key in an environment where demands on pharmaceutical and biotech customers continues to grow.  Roy has worked for both small local CROs as well as the larger CROs like ICON, TFS and Worldwide Clinical Trials and his experience in meeting clients challenges and ensuring the growth of companies is aligned with the customers needs has been the key to Roy’s success. He is highly customer focused with an ability to develop high performing teams whilst maintaining an holistic approach to business.

Dr Gordana Tonković

President, CRO

Dr Gordana Tonković

President, CRO

Gordana is a graduate of the University of Zagreb, Croatia, where she obtained her Doctor of Medicine, specializing in Neurology.

Since then, she has been working as an investigator in Phase II and Phase III trials in the area of neurology.

Gordana has deep expertise in clinical development, with over 15 years’ experience in the CRO industry including global Project Manager roles in Phase II and Phase III trials, clinical development planning and full clinical development leadership in Ergomed’s co-development programs.

Gordana has been in charge of the CRO business since 2018, when she successfully transitioned the business from a co-development model to a full service profitable business model.

Sally Amanuel

President, PrimeVigilance

Sally Amanuel

President, PrimeVigilance

Sally has over 20 years’ experience working in Regulatory Affairs and Compliance. As a regulatory expert she has a proven track record in driving transformational changes and delivering business results in highly regulated environments across Pharma, Biotech and CRO industries.
In her earlier role at Ergomed as the Head of the Regulatory Affairs and Clinical Delivery, Sally was responsible for integrating the CRO Regulatory function within PrimeVigilance, consolidating the PV Network, XEVMPD, Regulatory Intelligence and Regulatory Affairs teams. Prior to joining Ergomed, Sally held numerous leadership positions at WCT, PPD and Syneos as well as Biogen, Pfizer and GSK, where she led several successful turnarounds, redesigned and expanded service capabilities to exceed revenue targets and provided executive leadership on numerous companywide change initiatives.
Sally gained a BSc in Biotechnology from University College London (UCL), an MA in Biotechnological Law and Ethics from the University of Sheffield and an MBA from the University of Liverpool.

Sanja Jurić

General Counsel

Sanja Jurić

General Counsel

Sanja Juric joined Ergomed in 2016 after more than 30 years’ career in international law and after having assisted Ergomed as its outside advisor for more than 15 years.

Sanja holds degrees from the University of Zagreb (LLB, 1985) and the University of Fordham, School of Law, New York City (LLM in International Trade and Business Law, 1992). She has been admitted to the Bar of the State of New York since May 1993 and is listed as an arbitrator with the Chamber of Commerce in Croatia.

Sanja’s previous experience includes the position as the head of legal affairs of large private companies, as well as providing consulting to international businesses and organizations (including IFC, DEG, Avon, Kleeman, Herbalife) and cooperation with multinational law firms (Baker & McKenzie) focusing on cross-border transactions, primarily M&A. Sanja wrote extensively for several international M&A handbooks and participated for many years as an author in the World Bank series of “Doing Business”.